No definition available.
Disorders of myoneural junction and muscle in diseases classified elsewhere
DOID EFO Endpoint Browser PheWeb
G6_MYOMUSCINOTH
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
320 |
4. Check minimum number of eventsNone |
320 |
5. Include endpointsNone |
320 |
6. Filter based on genotype QC (FinnGen only) |
282 |
Control definitions (FinnGen only)
- Control exclude
- G6_MYONEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Disorders of myoneural junction and muscle in diseases classified elsewhere
based on the number of shared cases.
Similar with more cases:
- Diseases of the myoneural junction and muscle
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Neurological diseases
- Neurological diseases, wide definition
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1357 | 973 | 377 |
| Only index persons | 1184 | 865 | 319 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.01 |
| Only index persons | 0.03 | 0.03 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 61.99 | 62.44 | 60.81 |
| Only index persons | 61.00 | 61.15 | 60.58 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 282 | 216 | 66 |
| Unadjusted period prevalence (%) | 0.07 | 0.08 | 0.03 |
| Median age at first event (years) | 57.31 | 56.66 | 59.43 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 296
- Matched controls
- 2960
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
78.6
234.4
132
30
P01BA02
ATC
hydroxychloroquine; oral
18.2
138.8
146
150
G73.7*M35.0
ICD-10 Finland
Myopathy in sicca syndrome [Sjögren]
+∞
138.8
122
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
13.0
109.1
145
203
L04AX01
ATC
azathioprine; systemic
18.5
78.4
68
47
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
10.0
59.5
79
104
L04AA06
ATC
mycophenolic acid; systemic
21.7
49.2
38
20
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
7.6
48.1
81
139
L04AX03
ATC
methotrexate; systemic
6.9
46.9
89
173
G73.7
ICD-10 Finland
Myopathy in other diseases classified elsewhere
+∞
46.1
43
*
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
73.0
43.8
49
8
H02AB07
ATC
prednisone; oral
5.6
40.0
99
244
L01BA01
ATC
methotrexate; systemic
11.9
33.8
36
34
M05BA04
ATC
alendronic acid; oral
5.8
33.7
74
162
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.7
33.4
60
108
G73.7*M32.1
ICD-10 Finland
Myopathy in systemic lupus erythematosus
+∞
32.9
31
*
M32.1
ICD-10 Finland
Systemic lupus erythematosus with organ or system involvement
347.7
31.5
31
*
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
30.0
27.8
37
14
H02AB04
ATC
methylprednisolone; systemic
4.3
27.1
90
273
H02AB06
ATC
prednisolone; systemic
3.9
27.1
206
1089
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
6.8
25.9
44
74
G73.0*E05.9
ICD-10 Finland
Myasthenic syndromes in thyrotoxicosis [hyperthyroidism]
+∞
25.4
24
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.5
24.8
176
874
M79.0
ICD-10 Finland
Rheumatism, unspecified
8.0
23.8
34
47
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.3
22.7
69
194
M32.8
ICD-10 Finland
Other forms of systemic lupus erythematosus
236.8
21.9
22
*
G73.1*C80.99
ICD-10 Finland
Eaton-Lambert syndrome
+∞
21.1
20
*
L88
ICPC
Rheumatoid/seropositive arthritis
6.5
20.6
36
62
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
20.6
195
1106
G73.0*E11.4
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic amyotrophy
+∞
20.0
19
*
M32.0
ICD-10 Finland
Drug-induced systemic lupus erythematosus
213.7
19.8
20
*
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
5.3
19.1
42
90
G73.7*M34.8
ICD-10 Finland
Myopathy in scleroderma
202.3
18.8
19
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.0
18.7
134
641
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.1
18.6
58
165
C08CA05
ATC
nifedipine; systemic
5.3
18.4
40
85
H04.10
ICD-10 Finland
Dry eye syndrome
3.5
17.9
75
261
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.9
17.9
187
1089
M34.9
ICD-10 Finland
Systemic sclerosis, unspecified
101.2
17.8
19
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.1
17.5
54
152
E05.9
ICD-10 Finland
Thyrotoxicosis, unspecified
6.9
17.4
28
44
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.8
17.3
61
189
N06AX21
ATC
duloxetine; oral
3.5
17.0
71
246
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
7.8
16.8
24
33
G72.9
ICD-10 Finland
Myopathy, unspecified
179.7
16.7
17
*
N07AA02
ATC
pyridostigmine; systemic
63.6
15.9
18
*
K11.2
ICD-10 Finland
Sialoadenitis
6.5
15.9
27
45
G73.7*M05.3
ICD-10 Finland
Rheumatoid myopathy
+∞
15.8
15
*
H19.3*M35.0
ICD-10 Finland
Keratoconjunctivitis sicca
90.0
15.7
17
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.9
15.2
36
82
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.1
15.1
81
325
M35.1
ICD-10 Finland
Other overlap syndromes
84.4
14.7
16
*
G73.0*E10.4
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic amyotrophy
+∞
14.7
14
*
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
7.0
14.7
23
35
7100A
ICD-9 Finland
Diffuse diseases of connective tissue, Systemic lupus erythematosus
157.5
14.6
15
*
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
4.6
14.1
36
87
N06AA09
ATC
amitriptyline; systemic
3.6
14.0
53
171
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.8
13.8
46
136
Z01.8
ICD-10 Finland
Other specified special examinations
2.7
13.5
95
438
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.5
13.3
51
166
S01XA18
ATC
ciclosporin; ophthalmic
29.9
13.1
17
6
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.8
12.9
43
127
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
3.0
12.7
66
258
G05.8*M32.1
ICD-10 Finland
Encephalitis in systemic lupus erythematosus
+∞
12.6
12
*
73410
ICD-8 Finland
Diffuse diseases of connective tissue, Systemic lupus erythematosus
135.5
12.5
13
*
C03CA01
ATC
furosemide; systemic
2.5
12.5
115
600
NF1AA
NOMESCO Finland
Hip X-ray examination
3.5
12.2
47
153
E05.0
ICD-10 Finland
Thyrotoxicosis with diffuse goitre
5.4
12.2
25
50
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.4
11.9
31
76
N03AX16
ATC
[U] pregabalin
2.5
11.8
98
486
M34.8
ICD-10 Finland
Other forms of systemic sclerosis
+∞
11.5
11
*
G70.0
ICD-10 Finland
Myasthenia gravis
+∞
11.5
11
*
N08.5*M32.1
ICD-10 Finland
Glomerular disorders in systemic lupus erythematosus
124.7
11.5
12
*
R06.0
ICD-10 Finland
Dyspnoea
2.4
11.5
110
581
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.0
11.4
57
217
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
5.9
11.3
21
38
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.4
11.3
101
517
L04AA01
ATC
[U] ciclosporin
16.3
11.0
17
11
M79.7
ICD-10 Finland
Fibromyalgia
4.5
10.8
27
64
M32
ICD-10 Finland
Systemic lupus erythematosus
62.3
10.7
12
*
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.9
10.7
24
52
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.0
10.5
52
196
GD1AD
NOMESCO Finland
Thorax CT examination
3.9
10.5
33
93
G73.1
ICD-10 Finland
Lambert-Eaton syndrome
+∞
10.5
10
*
108
Kela drug reimbursment
Myasthenia gravis
+∞
10.5
10
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
3.0
10.4
51
192
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
5.6
10.3
20
38
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.1
10.3
46
164
SHA02
NOMESCO Finland
Stomatognathic treatment, basic
3.6
10.1
36
111
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.6
10.1
35
106
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.8
10.0
56
226
H03BB01
ATC
carbimazole; oral
4.3
10.0
27
68
XF400
NOMESCO Finland
ECG with 12 standard connections
2.7
9.9
61
259
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
4.4
9.6
25
61
NH3DA
NOMESCO Finland
Bilateral foot X-ray examination
7.3
9.5
22
32
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.6
9.5
33
100
M33.2
ICD-10 Finland
Polymyositis
103.2
9.5
10
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.5
9.4
70
325
X58
ICD-10 Finland
Exposure to other specified factors
2.7
9.4
60
259
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
9.4
84
425
M01AH02
ATC
rofecoxib; oral
2.7
9.3
57
241
M05BA07
ATC
risedronic acid; oral
4.8
9.2
21
46
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
5.0
9.2
20
42
XG410
NOMESCO Finland
Flow-volume spirometry
4.7
9.0
21
47
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.8
9.0
51
207
M34.1
ICD-10 Finland
CR(E)ST syndrome
24.9
9.0
12
5
N03AX12
ATC
[U] gabapentin; oral
2.5
8.9
69
326
R13
ICD-10 Finland
Dysphagia
3.2
8.9
38
131
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.6
8.9
61
273
JN3AD
NOMESCO Finland
Abdominal CT examination
2.7
8.8
52
215
UJF32
NOMESCO Finland
Coloscopy
2.2
8.8
97
534
NXL00
NOMESCO Finland
Biopsy of muscle
51.5
8.7
10
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.9
8.7
26
71
H53.1
ICD-10 Finland
Subjective visual disturbances
3.3
8.6
35
117
104
Kela drug reimbursment
Thyroid insufficiency
3.2
8.5
36
124
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.2
8.5
36
124
R50.9
ICD-10 Finland
Fever, unspecified
2.6
8.5
57
252
M34.0
ICD-10 Finland
Progressive systemic sclerosis
92.6
8.5
9
*
Z50.1
ICD-10 Finland
Other physical therapy
3.7
8.5
28
82
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.4
8.4
66
313
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
4.1
8.4
24
63
SBB10
NOMESCO Finland
Dental impressions
3.3
8.3
32
104
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
3.2
8.2
34
115
WX892
NOMESCO Finland
Monitored bed care
3.4
8.2
31
99
S01KA02
ATC
hypromellose; ophthalmic
7.2
8.2
19
28
WZC00
NOMESCO Finland
Treatment plan or consultation
2.1
8.2
125
776
H03AA01
ATC
levothyroxine sodium; systemic
2.2
8.1
94
525
E0000UV, ,
ATC
2.0
8.0
147
972
TGC00
NOMESCO Finland
Bronchial lavation
4.8
8.0
18
39
R4120
NOMESCO Finland
Occupational therapy
3.2
7.9
33
112
X59
ICD-10 Finland
Exposure to unspecified factor
2.3
7.9
68
336
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.0
7.8
36
130
ELA30
NOMESCO Finland
Biopsy of salivary gland
46.2
7.8
9
*
M03BA52
ATC
carisoprodol, combinations excl. psycholeptics; oral
4.0
7.7
22
58
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
2.9
7.7
38
143
J01MA12
ATC
levofloxacin; systemic
2.3
7.7
67
333
M01AH01
ATC
celecoxib; oral
2.3
7.6
71
362
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.3
7.6
29
93
K11.70
ICD-10 Finland
Hypoptyalism
25.8
7.6
10
*
K11.71
ICD-10 Finland
Xerostomy (dry mouth)
10.4
7.6
14
14
NA3EA
NOMESCO Finland
Lumbar spine X-ray examination with flexion
4.4
7.6
19
45
M01AE03
ATC
ketoprofen; systemic, rectal
2.0
7.6
129
827
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.4
7.5
57
266
C08CA02
ATC
felodipine; oral
2.9
7.5
36
133
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
3.1
7.5
33
116
M35.3
ICD-10 Finland
Polymyalgia rheumatica
3.7
7.4
24
69
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
8.7
7.4
15
18
L04AA13
ATC
[U] leflunomide
6.5
7.4
18
29
J02AC01
ATC
fluconazole; systemic
2.0
7.3
146
985
N17.9
ICD-10 Finland
Acute renal failure, unspecified
4.5
7.3
18
42
G70.8
ICD-10 Finland
Other specified myoneural disorders
+∞
7.3
7
*
N02AX02
ATC
tramadol; systemic, rectal
1.9
7.3
145
977
J01FF01
ATC
clindamycin; systemic
2.1
7.3
95
553
J01DB01
ATC
cefalexin; oral
2.6
7.2
257
2134
L28
ICPC
Limited function/disability (L)
2.2
7.2
76
408
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
2.6
7.2
43
179
N99
ICPC
Neurological disease other
12.4
7.1
12
10
SHA03
NOMESCO Finland
Stomatognathic treatment, demanding
4.1
7.1
20
52
SBA10
NOMESCO Finland
Measurement of salivary flow rate
10.4
7.1
13
13
R4110
NOMESCO Finland
Physiotherapy
2.0
7.1
102
614
A02BC03
ATC
lansoprazole; oral
2.0
7.1
105
639
A01AC01
ATC
triamcinolone; local oral
7.8
7.0
15
20
A02BC05
ATC
esomeprazole; systemic
1.9
6.9
140
945
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
6.4
6.9
17
28
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
6.4
6.9
17
28
UJF30
NOMESCO Finland
Ileoscopy through colon
2.5
6.9
46
202
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
11.3
6.9
12
11
P01BA01
ATC
chloroquine; systemic
17.2
6.8
10
6
G63.2*E10.4
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic polyneuropathy
41.0
6.8
8
*
H06.2*E05.9
ICD-10 Finland
Dysthyroid exophthalmos
41.0
6.8
8
*
M01AX17
ATC
nimesulide; oral
2.0
6.8
88
509
C03DA01
ATC
spironolactone; oral
2.5
6.8
47
210
XCK00
NOMESCO Finland
Perimetry
3.2
6.7
28
95
ND2BA
NOMESCO Finland
Hand and fingers extensive X-ray examination
5.7
6.7
18
33
SBB00
NOMESCO Finland
Clinical photography of mouth and teeth
4.2
6.7
18
45
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
3.6
6.7
22
64
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.6
6.7
42
179
R03BA08
ATC
ciclesonide; inhalant
2.7
6.7
38
154
WX408
NOMESCO Finland
General anesthesy, balanced
2.0
6.7
91
536
TEA00
NOMESCO Finland
Biopsy of lip
12.6
6.6
11
9
H26.3
ICD-10 Finland
Drug-induced cataract
12.6
6.6
11
9
E000001, ,
ATC
2.1
6.6
70
375
R4190
NOMESCO Finland
Nutritional therapy
3.8
6.6
20
55
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
3.4
6.6
24
75
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
3.0
6.6
29
102
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.2
6.6
27
91
S97
ICPC
Chronic ulcer skin
2.9
6.5
31
114
M13.9
ICD-10 Finland
Arthritis, unspecified
2.9
6.5
31
114
L04AD01
ATC
ciclosporin; systemic
7.7
6.5
14
19
N28
ICPC
Limited function/disability (N)
7.7
6.5
14
19
A02BC02
ATC
pantoprazole; systemic
2.0
6.5
220
1745
286
Kela drug reimbursment
Ciclosporin eye drop
71.3
6.5
7
*
M60.8
ICD-10 Finland
Other myositis
71.3
6.5
7
*
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
2.5
6.4
42
182
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
14.7
6.4
10
7
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
6.8
6.4
15
23
K44.9
ICD-10 Finland
Diaphragmatic hernia without obstruction or gangrene
2.7
6.4
37
151
NH1BA
NOMESCO Finland
Ankle extensive X-ray examination
6.2
6.4
16
27
XX9XE
NOMESCO Finland
Other ultrasound examination
11.4
6.3
11
10
WX002
NOMESCO Finland
Sedation and analgesia
2.1
6.3
72
396
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
2.2
6.3
57
286
G04BE03
ATC
sildenafil; oral
18.5
6.3
9
5
L94.0
ICD-10 Finland
Localized scleroderma [morphea]
18.5
6.3
9
5
M25.5
ICD-10 Finland
Pain in joint
1.9
6.3
118
771
7102A
ICD-9 Finland
Diffuse diseases of connective tissue, Sicca syndrome[SYNDROMA SICCUM PRIMARIUM]
+∞
6.3
6
*
N16.4*M32.1
ICD-10 Finland
Renal tubulo-interstitial disorders in systemic lupus erythematosus
+∞
6.3
6
*
G73.0
ICD-10 Finland
Myasthenic syndromes in endocrine diseases
+∞
6.3
6
*
M60.9
ICD-10 Finland
Myositis, unspecified
27.3
6.3
8
*
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
4.3
6.2
16
39
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
4.3
6.2
16
39
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
2.7
6.1
34
136
TQW40
NOMESCO Finland
Remowal of suture of skin
2.8
6.0
30
113
SAA04
NOMESCO Finland
Special examination of mouth
3.3
6.0
23
74
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.1
6.0
66
357
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
107
122
13.17
92.01
5.9
1.8
11.66
4.28
iu/ml
2.29
50
32
84
86
13.24
76.88
1.9
1.4
2.84
2.15
u/ml
0.63
40
16
84
86
13.24
76.88
1.9
1.3
6.27
1.75
u/ml
1.11
34
11
78
77
13.40
72.92
1.7
1.3
—
—
—
0
0
73
73
12.95
67.43
1.8
1.3
17.31
10.50
u/ml
—
15
8
48
32
17.71
55.79
1.5
1.2
70.11
94.40
u/ml
—
9
5
96
214
6.16
43.70
4.6
2.7
11.37
10.09
g/l
1.46
85
200
54
69
9.35
40.99
1.7
1.3
56.13
45.97
u/ml
0.18
17
12
167
836
3.29
22.58
4.6
2.0
293.30
153.49
u/l
0.50
161
797
71
217
3.99
20.74
1.8
2.9
65.35
67.31
g/l
1.05
63
204
238
1541
3.78
19.76
17.7
9.8
4.02
3.95
e9/l
0.20
223
1338
53
137
4.49
19.29
8.7
3.2
1.73
1.88
mmol/l
0.10
43
106
25
32
8.44
18.57
1.4
1.3
—
—
—
0
0
207
1282
3.04
17.50
3.8
2.6
81.13
79.02
nmol/l
0.46
195
1156
76
283
3.27
16.14
2.7
4.8
248.14
248.93
u/l
0.02
71
270
99
434
2.92
15.78
2.4
1.9
—
—
—
0
0
134
695
2.70
15.39
3.5
2.1
3.44
2.95
mg/l
1.28
120
593
216
1447
2.82
14.36
6.5
3.9
33.12
5.70
estimate
0.38
42
285
96
440
2.75
13.83
3.7
2.8
0.80
0.81
mmol/l
0.45
86
418
195
1256
2.62
13.79
10.9
6.0
1.22
1.22
mmol/l
0.89
186
1151
24
41
6.28
13.75
1.3
1.1
7.46
4.00
u/ml
0.36
13
19
213
1436
2.72
13.64
6.4
3.9
0.00
0.00
estimate
-0.00
39
277
81
343
2.87
13.53
11.8
5.1
1.05
1.04
mmol/l
0.16
74
310
189
1214
2.54
13.21
8.1
4.3
34.74
36.10
g/l
2.36
177
1143
36
92
4.32
13.15
2.5
1.5
—
—
—
0
0
214
1466
2.66
12.91
6.7
4.0
0.00
0.00
estimate
-0.00
36
262
205
1380
2.58
12.76
12.9
6.8
1.22
1.22
mmol/l
0.09
181
1193
25
48
5.60
12.72
1.5
1.4
—
—
—
0
0
22
39
6.01
12.14
1.3
1.1
2.73
1.21
u/ml
1.16
11
14
36
98
4.04
12.08
2.8
1.6
—
—
—
0
0
21
18
12.46
12.02
1.0
1.1
—
—
—
0
0
160
983
2.37
11.90
4.0
3.3
2.35
2.36
mmol/l
0.49
151
899
93
450
2.56
11.76
4.1
2.4
10.77
13.44
umol/l
3.42
83
419
39
116
3.72
11.56
2.3
2.1
1.71
1.60
g/l
0.19
31
104
33
87
4.14
11.55
3.2
2.7
—
—
—
0
0
37
107
3.81
11.41
1.6
2.4
2.85
3.02
g/l
0.37
32
99
155
957
2.30
11.18
7.2
3.2
—
—
—
0
0
29
71
4.42
11.15
1.2
1.9
—
—
—
0
0
61
246
2.86
10.98
2.0
2.4
0.21
0.22
g/l
0.66
56
229
21
40
5.57
10.75
1.1
1.5
—
—
—
0
0
33
93
3.87
10.54
1.6
1.4
304.94
307.67
ug/g
0.03
18
51
145
888
2.24
10.46
6.0
3.3
23.65
120.13
e6/l
0.71
120
678
111
612
2.30
10.29
5.3
2.7
3.91
6.96
e6/l
1.24
104
557
85
417
2.46
10.27
4.2
2.4
2.14
2.36
g/l
2.41
75
385
37
115
3.53
10.25
1.6
2.3
7.13
7.44
g/l
0.48
32
107
37
115
3.53
10.25
1.6
2.3
4.04
4.29
g/l
1.00
32
107
37
115
3.53
10.25
1.6
2.3
3.35
3.97
g/l
1.11
32
107
136
821
2.21
10.07
5.3
3.2
2329.71
1128.58
ng/l
1.17
118
691
133
797
2.21
10.01
6.3
4.1
0.00
0.01
estimate
0.50
37
269
119
684
2.24
9.91
1.5
1.3
3.51
1.46
u/ml
0.36
20
179
16
13
12.93
9.47
1.1
1.0
—
—
—
0
0
64
285
2.59
9.42
2.3
1.9
329.69
386.25
nmol/l
1.19
59
270
180
1239
2.16
9.27
18.7
11.6
1.20
1.20
inr
0.04
151
1000
177
1211
2.15
9.26
2.6
2.2
102.75
98.53
pmol/l
0.57
101
609
252
1998
2.76
9.23
13.2
4.5
17.36
11.80
mm/h
6.92
246
1850
79
392
2.38
9.20
4.5
2.4
20.25
22.63
%
0.94
70
365
38
130
3.21
9.04
2.2
2.3
44.09
40.64
u/l
0.41
33
116
24
60
4.26
8.97
2.5
1.7
125.93
129.44
g/l
0.25
15
45
43
159
2.99
8.97
4.5
3.8
4.08
4.46
pmol/l
1.57
38
138
155
1019
2.09
8.88
6.5
3.8
36.82
35.35
ng/l
0.05
120
710
125
759
2.12
8.84
6.0
3.1
0.26
0.46
e6/l
0.98
99
544
54
228
2.67
8.81
5.9
3.5
102.99
83.16
ng/l
0.73
45
201
32
100
3.47
8.78
1.7
2.8
0.11
0.75
g/l
1.42
26
91
20
44
4.80
8.73
1.5
1.2
—
—
—
0
0
30
92
3.52
8.46
1.7
4.3
45.33
122.17
mg/l
0.64
25
81
30
92
3.52
8.46
1.7
4.3
33.05
31.91
mg/l
0.08
24
81
17
20
8.94
8.42
1.2
1.0
—
—
—
0
0
99
561
2.15
8.28
1.5
1.4
47.62
30.93
iu/ml
0.98
45
183
49
205
2.67
8.12
1.8
1.4
—
—
—
0
0
22
56
4.16
8.04
11.4
4.6
1403.71
141.50
iu/ml
—
7
6
19
43
4.65
8.02
1.2
1.2
—
—
—
0
0
24
66
3.87
7.91
1.9
1.6
—
—
—
0
0
129
821
2.01
7.80
1.8
1.7
21.28
21.45
nmol/l
0.04
112
691
84
456
2.18
7.77
2.3
1.7
1271.71
1148.11
nmol/l
0.61
70
344
17
24
7.44
7.59
1.5
1.3
—
—
—
0
0
27
83
3.48
7.59
1.7
4.0
1.44
3.82
ratio
1.16
17
43
17
25
7.15
7.40
1.4
1.2
—
—
—
0
0
18
29
6.54
7.36
1.4
1.2
—
—
—
0
0
17
26
6.87
7.22
1.5
1.2
—
—
—
0
0
17
26
6.87
7.22
1.5
1.2
—
—
—
0
0
18
43
4.39
7.12
2.1
1.7
—
—
—
0
0
178
1293
1.94
7.08
4.7
3.0
135.02
100.41
ug/l
1.18
159
1208
30
104
3.10
6.97
1.7
2.2
11.53
10.35
g/l
0.41
25
95
38
153
2.70
6.76
1.8
1.7
—
—
—
0
0
108
678
1.93
6.55
4.1
2.9
347.87
333.95
umol/l
0.55
94
596
129
860
1.89
6.50
3.5
2.4
53.86
66.72
u/l
1.00
117
792
23
71
3.43
6.42
2.1
1.5
—
—
—
0
0
101
627
1.93
6.29
2.1
1.6
1.10
1.12
mg/l
0.04
82
504
62
323
2.16
6.25
1.9
1.9
—
—
—
0
0
13
17
7.94
6.19
1.3
1.1
—
—
—
0
0
87
520
1.95
6.02
1.3
1.3
16.81
10.53
u/ml
0.20
18
187
95
586
1.91
5.99
2.8
2.6
2.46
2.45
mmol/l
0.20
87
533
40
179
2.43
5.73
1.5
1.3
246.99
358.54
u/ml
0.22
33
163
31
123
2.70
5.67
1.5
1.3
—
—
—
0
0
22
72
3.22
5.62
1.9
1.6
—
—
—
0
0
14
24
6.07
5.60
2.4
2.0
—
—
—
0
0
199
1566
1.83
5.49
7.6
4.7
6.53
6.57
mmol/l
0.08
188
1479
21
68
3.25
5.46
2.4
1.4
5130.20
16776.93
e6/l
0.63
15
43
21
69
3.20
5.33
2.6
1.3
—
—
—
0
0
20
64
3.28
5.30
1.6
1.5
—
—
—
0
0
188
1464
1.78
5.27
8.0
6.1
9.24
10.61
umol/l
2.25
177
1395
18
54
3.48
5.25
1.7
1.5
—
—
—
0
0
14
27
5.39
5.15
2.4
1.9
—
—
—
0
0
62
347
2.00
5.11
4.8
4.8
31.96
32.83
%
0.30
48
222
9
9
10.27
5.06
2.0
2.0
—
—
—
0
0
9
9
10.27
5.06
2.0
2.0
—
—
—
0
0
9
9
10.27
5.06
2.0
2.0
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
61
3.26
5.01
3.5
2.4
0.21
0.40
iu/ml
1.71
11
32
15
41
3.80
4.99
1.5
1.7
—
—
—
0
0
98
642
1.79
4.96
3.1
2.1
—
—
—
0
0
23
84
2.88
4.90
1.4
1.1
—
—
—
0
0
12
22
5.64
4.65
1.1
1.0
—
—
—
0
0
7
5
14.29
4.59
1.3
1.2
—
—
—
0
0
10
15
6.86
4.50
2.5
1.7
—
—
—
0
0
10
15
6.86
4.50
2.5
1.7
—
—
—
0
0
10
15
6.86
4.50
2.5
1.7
—
—
—
0
0
10
15
6.86
4.50
2.5
1.7
—
—
—
0
0
125
902
1.67
4.36
3.9
3.0
30.96
28.74
u/l
0.63
115
856
11
20
5.67
4.33
1.4
1.0
—
—
—
0
0
24
98
2.58
4.17
1.7
1.7
—
—
—
0
0
16
52
3.20
4.15
1.5
1.6
—
—
—
0
0
83
543
1.73
4.12
1.7
1.8
478.96
25771390.39
pmol/l
0.50
68
454
8
10
8.18
4.08
1.3
1.3
—
—
—
0
0
16
53
3.13
4.03
1.4
1.3
—
—
—
0
0
74
472
1.76
4.01
4.6
2.8
0.53
0.96
e6/l
2.04
47
234
53
307
1.88
3.92
2.0
2.0
—
—
—
0
0
160
1251
1.61
3.91
3.1
2.5
—
—
estimate
—
0
0
11
23
4.92
3.91
2.4
1.7
—
—
—
0
0
11
23
4.92
3.91
2.4
1.7
—
—
—
0
0
11
23
4.92
3.91
2.4
1.7
—
—
—
0
0
139
1059
1.59
3.74
6.4
3.8
0.00
0.02
estimate
0.68
35
225
52
306
1.85
3.66
6.9
7.5
1.16
1.02
mmol/l
0.08
44
261
12
30
4.12
3.64
4.3
1.5
0.84
0.28
mmol/l
0.21
12
30
20
80
2.61
3.63
2.5
1.8
9.13
5.55
iu/l
—
7
33
7
9
7.93
3.57
1.0
1.0
1783.29
1714.11
miu/ml
—
7
9
21
87
2.52
3.56
1.2
1.2
—
—
—
0
0
11
26
4.35
3.54
1.2
1.1
—
—
—
0
0
9
17
5.42
3.53
1.3
1.0
—
—
—
0
0
8
13
6.29
3.52
2.6
2.2
—
—
—
0
0
8
13
6.29
3.52
1.4
1.3
—
—
—
0
0
6
6
10.17
3.51
1.0
1.2
102.83
103.17
%
—
6
6
19
76
2.60
3.45
2.2
2.5
10.89
12.42
mg/l
0.43
19
70
18
70
2.67
3.45
3.9
3.3
2.43
1.50
index
—
7
46
11
27
4.19
3.43
1.9
1.3
—
—
—
0
0
39
213
1.96
3.43
2.3
2.4
3.89
6.28
ug/l
0.79
28
189
15
53
2.93
3.41
5.9
2.2
8.49
7.73
pmol/l
0.15
15
53
7
10
7.14
3.38
1.7
1.4
—
—
—
0
0
13
38
3.53
3.35
1.2
1.3
—
—
—
0
0
13
38
3.53
3.35
1.2
1.3
—
—
—
0
0
12
33
3.75
3.33
1.8
1.4
—
—
—
0
0
240
2115
1.71
3.27
6.8
4.7
15.20
14.79
pmol/l
1.54
224
1931
13
39
3.44
3.27
1.2
1.3
—
—
—
0
0
13
39
3.44
3.27
1.2
1.3
—
—
—
0
0
13
39
3.44
3.27
1.2
1.3
—
—
—
0
0
10
24
4.27
3.22
1.8
1.2
104.70
104.83
pmol/l
—
10
24
7
11
6.49
3.20
1.7
1.5
—
—
—
0
0
104
762
1.56
3.20
5.7
3.3
0.00
0.00
estimate
0.50
35
223
207
1769
1.57
3.10
5.2
3.1
49.69
45.57
u/l
0.31
194
1667
6
8
7.62
3.07
1.0
3.7
39.75
43.90
g/l
—
6
8
7
12
5.94
3.04
1.7
1.5
—
—
—
0
0
9
21
4.39
3.02
1.8
2.4
—
—
—
0
0
5
5
10.14
2.99
1.2
1.2
—
—
—
0
0
12
38
3.25
2.88
1.3
1.3
—
—
—
0
0
6
9
6.78
2.88
1.2
1.1
—
—
—
0
0
42
250
1.79
2.85
5.4
3.3
—
—
—
0
0
11
33
3.42
2.84
1.8
1.3
—
—
—
0
0
8
18
4.54
2.81
1.4
1.3
—
—
—
0
0
10
28
3.66
2.81
1.3
1.0
—
—
—
0
0
49
308
1.71
2.76
8.5
6.6
—
—
—
0
0
120
932
1.48
2.73
5.6
3.2
6.31
7.11
mmol/l
1.37
104
779
6
10
6.10
2.71
1.0
1.3
—
—
—
0
0
6
10
6.10
2.71
1.0
1.1
—
—
—
0
0
38
223
1.81
2.70
1.8
1.5
—
—
—
0
0
10
30
3.41
2.63
1.3
1.0
—
—
—
0
0
17
75
2.34
2.56
1.5
1.2
—
—
—
0
0
5
7
7.24
2.56
1.0
1.3
—
—
—
0
0
190
2147
0.68
2.53
44.4
20.1
328.69
331.13
g/l
2.82
190
2138
17
76
2.31
2.49
1.5
2.0
3425.66
8132.38
u/l
—
7
25
14
57
2.53
2.48
2.1
1.5
—
—
—
0
0
8
21
3.88
2.48
1.1
1.1
—
—
—
0
0
62
427
1.57
2.44
5.1
2.9
3.40
2.86
e6/l
0.17
35
189
115
902
1.45
2.43
6.8
4.0
14.87
7.11
mg/mmol
1.21
75
536
9
27
3.40
2.41
1.6
1.2
—
—
—
0
0
5
8
6.33
2.38
3.2
1.9
0.61
0.61
mmol/l
—
5
8
10
33
3.10
2.38
1.1
1.2
—
—
—
0
0
35
212
1.74
2.26
7.4
3.5
1.22
1.23
mmol/l
0.28
30
185
9
29
3.17
2.24
1.1
1.2
—
—
—
0
0
67
479
1.52
2.23
1.7
1.5
—
—
—
0
0
7
19
3.75
2.16
2.9
1.4
142.64
87.44
ng/l
—
7
19
8
25
3.26
2.11
1.0
1.0
—
—
—
0
0
9
31
2.96
2.09
1.4
1.2
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
10
5.06
2.08
1.4
2.1
104.80
117.40
%
—
5
10
6
15
4.06
2.05
1.3
3.4
1156.67
619.60
u/ml
—
6
15
6
15
4.06
2.05
1.8
1.1
—
—
—
0
0
42
277
1.60
1.98
3.4
2.3
35.14
29.36
u/l
0.84
35
237
40
262
1.61
1.94
7.4
3.7
5.78
5.84
kpa
0.17
40
257
44
296
1.57
1.92
2.4
2.4
3.91
7.02
umol/l
3.34
35
259
27
161
1.74
1.86
7.2
3.4
23.34
24.61
mmol/l
1.87
27
161
8
29
2.81
1.80
1.5
2.0
—
—
—
0
0
11
47
2.39
1.80
1.5
1.5
—
—
—
0
0
11
47
2.39
1.80
1.5
1.5
—
—
—
0
0
33
212
1.63
1.74
2.4
2.4
56.37
68.21
ml/min/173m2
1.09
19
86
42
287
1.54
1.72
1.6
1.9
1.51
1.47
%
0.17
34
253
5
13
3.89
1.72
1.0
1.0
—
—
—
0
0
5
13
3.89
1.72
1.2
1.4
95.80
94.69
%
—
5
13
177
1554
1.35
1.71
3.2
3.1
—
—
—
0
0
14
69
2.08
1.67
1.4
1.2
—
—
—
0
0
10
41
2.49
1.66
1.2
1.1
—
—
—
0
0
70
535
1.40
1.64
5.7
3.8
946.62
256.08
ng/l
0.45
57
409
271
2570
1.64
1.60
40.0
15.0
24.55
22.96
mg/l
0.33
253
2082
50
364
1.45
1.52
7.7
6.7
103.74
104.03
mmol/l
0.18
50
364
31
205
1.57
1.48
1.3
1.3
179.30
172.81
u/ml
—
10
91
260
2455
1.49
1.42
8.4
5.8
1.80
1.89
mu/l
0.68
245
2260
13
67
1.98
1.40
1.2
1.7
5.02
4.49
mmol/24h
0.26
13
59
68
533
1.36
1.36
1.5
1.5
—
—
—
0
0
78
630
1.32
1.28
7.4
4.3
1.02
1.02
kg/l
0.70
64
420
7
31
2.29
1.11
1.1
1.2
—
—
—
0
0
30
212
1.46
1.09
2.2
3.0
55.50
99.08
u/ml
0.33
30
206
25
173
1.49
1.01
7.7
9.5
94.21
93.78
%
0.13
25
173
9
48
1.90
1.01
1.1
1.1
—
15.29
—
0
18
260
2486
1.38
1.01
31.4
15.2
77.31
79.83
ml/min/173m2
0.97
251
2301
8
44
1.84
0.86
3.9
1.3
—
—
nmol/l
—
0
0
21
147
1.46
0.82
1.4
1.4
—
—
—
0
0
12
74
1.65
0.79
1.2
1.3
—
—
—
0
0
0
26
0.00
0.79
0.0
2.5
—
13.40
—
0
26
11
67
1.67
0.76
1.2
1.1
—
5.25
—
0
11
7
38
1.86
0.74
1.4
1.3
3.33
9.24
u/ml
—
7
38
14
95
1.50
0.65
1.2
1.2
—
—
—
0
0
5
29
1.74
0.64
1.6
1.2
—
—
—
0
0
5
29
1.74
0.64
1.6
1.2
—
—
—
0
0
37
299
1.27
0.63
3.0
4.4
3.98
22.31
ug/l
0.71
28
249
5
30
1.68
0.61
7.2
3.0
4.78
3.16
nmol/l
—
5
30
6
37
1.63
0.56
3.5
3.9
—
—
—
0
0
13
95
1.39
0.44
1.2
1.2
—
—
—
0
0
28
231
1.23
0.43
2.0
1.8
—
—
—
0
0
257
2508
1.19
0.42
6.3
5.2
5.94
5.91
mmol/l
0.12
235
2311
273
2774
0.80
0.42
55.7
23.4
91.59
91.27
fl
0.49
273
2744
0
15
0.00
0.41
0.0
8.3
—
42.40
—
0
5
30
251
1.22
0.41
2.0
2.0
—
—
—
0
0
6
86
0.69
0.33
1.5
1.6
1384.03
920.02
mu/l
—
6
71
6
86
0.69
0.33
1.8
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
3.2
—
4.59
—
0
10
0
10
0.00
0.21
0.0
3.2
—
10.88
—
0
10
0
12
0.00
0.21
0.0
1.0
—
23.77
—
0
12
12
100
1.21
0.18
1.4
1.4
—
—
—
0
0
13
111
1.18
0.16
1.4
1.3
0.32
0.30
mg/l
—
5
38
33
357
0.91
0.15
3.9
4.8
25.21
22.59
%
0.33
15
174
9
83
1.09
0.15
1.1
1.1
1.74
1.58
g/l
—
9
83
249
2460
1.08
0.14
8.3
6.4
39.92
39.13
mmol/mol
0.56
233
2308
246
2431
1.07
0.13
5.0
4.3
1.38
1.26
mmol/l
1.59
221
2228
273
2710
1.09
0.11
45.8
20.1
83.53
73.81
umol/l
2.40
273
2673
5
44
1.14
0.10
1.0
1.2
27.84
27.51
u/l
—
5
38
10
87
1.15
0.09
1.7
1.1
1.05
0.91
g/l
—
10
87
16
147
1.09
0.07
1.1
1.0
—
—
—
0
0
11
99
1.12
0.06
1.3
1.5
—
—
—
0
0
26
274
0.94
0.06
3.8
3.1
0.74
0.73
ug/l
0.01
20
170
15
142
1.06
0.02
4.7
2.5
0.57
0.61
%
0.30
15
142
256
2552
1.02
0.01
5.9
5.2
1.51
1.54
mmol/l
0.57
235
2361
11
104
1.06
0.01
1.8
1.8
—
—
—
0
0
260
2601
1.00
0.00
6.7
6.1
2.62
2.74
mmol/l
1.45
240
2412
121
1211
1.00
0.00
2.0
1.9
1.56
1.34
mmol/l
0.47
99
1026
257
2567
1.01
0.00
5.9
5.3
4.62
4.73
mmol/l
0.99
238
2387
15
145
1.04
0.00
4.1
2.5
1.04
1.17
%
0.40
15
145
13
134
0.97
0.00
1.9
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.17
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_MYOMUSCINOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MYOMUSCINOTH | 2.496 [2.04, 3.06] | < 0.001 |
| Birth year | 1.002 [0.99, 1.01] | 0.715 |
During the follow-up period (1.1.1998 — 31.12.2019), 313 out of 874 females with G6_MYOMUSCINOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MYOMUSCINOTH | 2.303 [1.64, 3.22] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 124 out of 312 males with G6_MYOMUSCINOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_MYOMUSCINOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.284% | 0.376% |
| 5 | 1.534% | 2.586% |
| 10 | 3.878% | 6.089% |
| 15 | 7.889% | 11.542% |
| 20 | 14.235% | 18.932% |
Relationships between endpoints
↥Index endpoint: G6_MYOMUSCINOTH – Disorders of myoneural junction and muscle in diseases classified elsewhere
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data